150 mg/ml
Trade Name
Evkeeza
Concentrate for Solution for Infusion
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Evinacumab is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and paediatric patients aged 5 years and older with homozygous familial hypercholesterolaemia (HoFH).